Table 2.

Multivariate analysis of both clinical and genomic variables for independent survival predictors in MPNST patients

aCGH test cohort (N = 36)TMA validation cohort (N = 87)
Parameter nMedian survivalPaHRbPbnMedian survivalPaHRbPb
LocationCentral1712 (5–18)0.0522.82 (1.15–6.92)0.0243227 (12–39)0.879
Peripheral1932 (15–112)5519 (11–52)
Tumor typePrimary3216 (12–52)0.6536830 (16–52)0.0451.41 (1.02–1.94)0.038
Recurrent412 (6–30)1218 (6–42)
Metastatic78 (4–10)
GradeLow518 (5–31)0.429916 (11–31)0.026
High3115 (12–32)7814 (6–124)
MetastasisYes1315 (12–32)0.223
No1510 (6–60)
RecurrenceYes2024 (10–112)0.2482028 (10–72)0.555
No1615 (12–32)6719 (12–37)
NF1 associatedYes2218 (6–52)0.9192533 (11–92)0.402
No1415 (12–112)6217 (12–39)
Age≤20442 (10–52)0.1261583 (15–132)0.124
21–3075 (4–112)1726 (6–54)
31–401215 (6–48)2015 (5–142)
>401312 (4–24)3516 (4–140)
GenderMale1612 (10–112)0.2813919 (10–42)0.468
Female2018 (15–52)4828 (13–51)
CDK4 gainYes912 (4–15)0.0214.22 (1.43–12.44)0.009
No2724 (12–112)
CDK4 amplificationYes1210 (5–16)0.0232.04 (1.03–4.04)0.041
No6731 (16–51)
FOXM1 gainYes1112 (6–17)0.016
No2532 (12–112)
FOXM1 expressionHigh3415 (8–29)0.0051.93 (1.12–3.31)0.017
Low4839 (14–84)
NOL1 gainYes912 (4–15)0.034
No2724 (12–112)
SOX5 gainYes1112 (6–17)0.024
No2532 (12–112)
SOX5 expressionHigh2318 (11–42)0.553
Low3714 (9–31)
MYC gainYes1615 (6–52)0.459
No2024 (12–112)
MYC expressionHigh2516 (10–30)0.045
Low5228 (12–54)
TP53 expressionHigh2733 (15–66)0.126
Low5415 (10–29)

NOTE: Numbers in parenthesis are 95% CI.

aUnivariate Breslow method.

bMultivariate Cox regression.